Patent · US Active

Compounds which modulate the CB2 receptor

US8829034B2 · kind B2 · utility

6Cited by

33References

9Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Angela Berry · Gaylordsville, US
Pier Francesco Cirillo · Woodbury, US
Eugene Richard Hickey · Danbury, US
Doris Riether · Biberach an der Riß, DE
David Thomson · Ridgefield, US
Renee M. Zindell · New Milford, US
Nigel James Blumire · Biggenden, AU
Chandana Parke · Manchester, GB
Monika Ermann · Wantage, GB
James Edward Jenkins · Hungerford, GB
Innocent Mushi · Felton, GB
Christopher Francis Palmer · Abingdon, GB
Malcolm Taylor · Biggenden, AU

Key dates

Filing date	Feb 8, 2011
Grant date	Sep 9, 2014
Priority date	—
Expiry date	Jan 26, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds of formula (I)are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.